

Recent Anti-platelet Therapy Revealing Underlying Undiagnosed Gastrointestinal Stromal Tumor in Otherwise Healthy Patient

Shehriyar Mehershahi¹, Haider Ghazanfar², Danial H. Shaikh¹, Ahmed Baiomi², Ariyo Ihimoyan¹

1. Gastroenterology, BronxCare Health System, Bronx, USA 2. Internal Medicine, BronxCare Health System, Bronx, USA

Corresponding author: Shehriyar Mehershahi, sh3hriyar@hotmail.com

Abstract

Gastrointestinal stromal tumors (GIST) are uncommon tumors of the gastrointestinal (GI) tract that arise from primitive mesenchymal cells. Usually, GIST presents as chronic gastrointestinal symptoms or obscure gastrointestinal bleed. Not many cases have been reported in the literature with acute symptoms in the setting of recent aspirin use. We report a case of 70-year-old male otherwise healthy who presented to the hospital with the complaint of black tarry stool for the past two days after taking one tablet of aspirin once a day for two days. The patient underwent upper endoscopy which showed a moderate size polypoid mass in the gastric fundus. Initially, standard endoscopic biopsy was negative for malignancy, due to high suspicion for GIST, later the patient underwent upper endoscopic ultrasound with fine-needle aspiration which confirmed low-grade GIST.

Categories: Gastroenterology, Oncology

Keywords: gist, aspirin, upper gastrointestinal bleed

Introduction

Gastrointestinal stromal tumors (GISTs) are a group of stromal or mesenchymal neoplasms affecting the gastrointestinal tumors. Although GISTs are relatively uncommon (<1% of all gastrointestinal neoplasms) compared with adenocarcinoma, they are the most prevalent mesenchymal tumors of the gastrointestinal tract [1]. GIST is distinguished from myogenic or neurogenic tumors due to the expression and mutations of KIT in the c-kit. Mutation in the c-kit gene is associated with aggressive features and poor prognosis [2]. The stomach and small intestine are the most common locations [3]. GISTs are known to grow from intestinal cells of Cajal due to mutation of KIT and platelet-derived growth factor receptor alpha (PDGFRA) [4,5]. The diagnosis of gastric GISTs is often delayed because these tumors cause no characteristic symptoms. We present an acute obscure GI bleed with underlying undiagnosed GIST in a patient taking two tablets of aspirin for shoulder pain.

Case Presentation

Our patient is a 70-year-old male who presented to the hospital with the complaint of generalized weakness, feeling dizzy and black tarry stool for the past two days. The patient states that he took one tablet of aspirin once a day for two days for shoulder pain prior to the start of the black tarry stool. The patient denies any previous similar episode, hematochezia, weight loss, loss of appetite or constitutional symptoms. Past medical history is significant for hypertension and hyperlipidemia well controlled without medication. The patient's past surgical history is significant for appendectomy in 2016. No significant family history of gastrointestinal malignancy. The patient smokes 2-3 cigarettes a day for the past 30 years, drinks five to six beers on the weekends, denies using any illicit substance.

In the emergency department the patient was found to be afebrile and had a blood pressure of 119/72 mmHg with the pulse rate of 81 bpm. On physical exam the patient was not in distress, the abdomen was soft, non-tender, non-distended. The digital rectal examination showed no hemorrhoids or hematochezia, finger staining with melanotic stool, no hematochezia. The rest of the physical examination was unremarkable. The patient was found to have hemoglobin of 8.3 g/dL on the presentation. The patient's baseline hemoglobin was 14.1 g/dL. On anemia workup the patient was found to have normal serum ferritin, folate, Vitamin B12, and iron serum levels. The patient underwent upper endoscopy which showed a moderate size polypoid mass in the gastric fundus with no ulceration or stigmata of bleeding. This has been shown in Figure 1. The biopsy revealed gastric antral mucosa with focal mild chronic inflammation and foveolar reactive changes. The patient underwent computed tomography (CT) abdomen and pelvis with contrast material which showed gastric mass 3.8 x 2.7 cm without evidence of metastatic disease to the chest, abdomen or pelvis. This has been shown in Figure 2.

Received 03/22/2020
Review began 03/25/2020
Review ended 03/25/2020
Published 03/28/2020

© Copyright 2020

Mehershahi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Mehershahi S, Ghazanfar H, Shaikh D H, et al. (March 28, 2020) Recent Anti-platelet Therapy Revealing Underlying Undiagnosed Gastrointestinal Stromal Tumor in Otherwise Healthy Patient. Cureus 12(3): e7450. DOI 10.7759/cureus.7450




FIGURE 1: Esophagogastroduodenoscopy




FIGURE 2: CT abdomen and pelvis with contrast material

The patient underwent upper endoscopic ultrasound which showed oval intramural (subepithelial) lesion, located in the fundus 2.5 x 3 cm with a central cystic area. The lesion appeared to originate from within the muscularis propria (layer 4). This has been shown in Figure 3. Fine needle aspiration (FNA) was obtained for pathology. The pathology of the sample showed low-grade gastrointestinal stromal tumors (GIST). On immunohistochemical stain, the tumor cells were found to be positive for CD117, DOG1, and CD34, and it was negative for SMA antibodies. The patient underwent exploratory laparotomy and partial gastrectomy. Pathology tissue analysis confirmed gastrointestinal stromal tumor, spindle cell type measured 3.5 cm in greatest dimension, mitotic rate 7/5 mm², high grade, and no lymphovascular invasion was seen. The

lead to delay in diagnosis and treatment of these patients.

This case reinforces to prompt physicians to think of GIST as a differential in the acute presentation of upper GI bleed in the setting of recent aspirin use in an otherwise healthy patient. Patients with un-diagnosed GIST usually present with obscure or overt GI bleeding while on chronic antiplatelet therapy [16]. In our case the patient took two aspirin for two days and presented with an obscure GI bleed.

Conclusions

Chronic antiplatelet therapy in the setting of underlying undiagnosed GIST can manifest with obscure or overt gastrointestinal bleed. Not many cases have been reported in the literature with early upper GI bleed in the setting of recent aspirin use in a patient with underlying un-diagnosed GIST. This case reinforces to prompt physicians to think of GIST as a differential in the acute presentation of upper GI bleed in the setting of two tablets of baby aspirin use in an otherwise healthy patient. Early diagnosis and prompt treatment are essential in treating GISTs.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Rubin BP, Heinrich MC, Corless CL: Gastrointestinal stromal tumour. *Lancet*. 2007, 369:1731-1741. [10.1016/S0140-6736\(07\)60780-6](https://doi.org/10.1016/S0140-6736(07)60780-6)
- Nishida T, Hirota S: Biological and clinical review of stromal tumors in the gastrointestinal tract. *Histol Histopathol*. 2000, 15:1295-1301. [10.14670/HH-15.1295](https://doi.org/10.14670/HH-15.1295)
- Tran T, Davila JA, El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. *Am J Gastroenterol*. 2005, 100:162-168. [10.1111/j.1572-0241.2005.40709.x](https://doi.org/10.1111/j.1572-0241.2005.40709.x)
- Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science*. 1998, 279:577-580. [10.1126/science.279.5350.577](https://doi.org/10.1126/science.279.5350.577)
- Fülöp E, Marcu S, Milutin D, Borda A: Gastrointestinal stromal tumors: review on morphology, diagnosis and management. *Rom J Morphol Embryol*. 2009, 50:319-326.
- Nilsson B, Bümbling P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the imatinib mesylate era - A population-based study in western Sweden. *Cancer*. 2005, 103:821-829. [10.1002/cncr.20862](https://doi.org/10.1002/cncr.20862)
- Miettinen M, Makhoul H, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. *Am J Surg Pathol*. 2006, 30:477-489. [10.1097/00000478-200604000-00008](https://doi.org/10.1097/00000478-200604000-00008)
- Pang T, Zhao Y, Fan T, et al.: Comparison of safety and outcomes between endoscopic and surgical resections of small (≤ 5 cm) primary gastric gastrointestinal stromal tumors. *J Cancer*. 2019, 10:4132-4141. [10.7150/jca.29443](https://doi.org/10.7150/jca.29443)
- Hedenbro JL, Ekelund M, Wetterberg P: Endoscopic diagnosis of submucosal gastric lesions - The results after routine endoscopy. *Surg Endosc*. 1991, 5:20-23. [10.1007/bf00591381](https://doi.org/10.1007/bf00591381)
- Liu YM, Yang XJ: Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop. *World J Gastroenterol*. 2017, 23:2795-2801. [10.3748/wjg.v23.i15.2795](https://doi.org/10.3748/wjg.v23.i15.2795)
- Chiyo T, Kobara H, Mori H, Katsuki N, Haba R, Masaki T: Submucosal endoscopic sampling for indefinite gastric linitis plastica infiltrating into the submucosal layer. *J Gastrointest Liver Dis*. 2015, 24:375-378. [10.15403/jgld.2014.1121.243.chy](https://doi.org/10.15403/jgld.2014.1121.243.chy)
- Chien CH, Chien RN, Yen CL, et al.: The role of endoscopic ultrasonography examination for evaluation and surveillance of gastric subepithelial masses. *Chang Gung Med J*. 2010, 33:73-81.
- Al-Haddad M, Savabi MS, Sherman S, et al.: Role of endoscopic ultrasound-guided fine-needle aspiration with flow cytometry to diagnose lymphoma: a single center experience. *J Gastroenterol Hepatol*. 2009, 24:1826-1833. [10.1111/j.1440-1746.2009.06005.x](https://doi.org/10.1111/j.1440-1746.2009.06005.x)
- Trupiano JK, Stewart RE, Misick C, Appelman HD, Goldblum JR: Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. *Am J Surg Pathol*. 2002, 26:705-714. [10.1097/00000478-200206000-00005](https://doi.org/10.1097/00000478-200206000-00005)
- Liu Q, Li Y, Dong M, Kong F, Dong Q: Gastrointestinal bleeding is an independent risk factor for poor prognosis in GIST patients. *BioMed Res Int*. 2017, 2017:6. [10.1155/2017/7152406](https://doi.org/10.1155/2017/7152406)
- Fukuyama K, Fujikawa T, Kuramitsu S, Tanaka A: Successful treatment of bleeding large duodenal gastrointestinal stromal tumour in a patient under dual antiplatelet therapy after recent drug-eluting coronary stent implantation. *BMJ Case Rep*. 2014, 2014:bcr2014204462. [10.1136/bcr-2014-204462](https://doi.org/10.1136/bcr-2014-204462)
- Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin Diagn Pathol*. 2006, 23:70-83. [10.1053/j.semdp.2006.09.001](https://doi.org/10.1053/j.semdp.2006.09.001)
- Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal)

tumors: dependence on anatomic site. *Am J Surg Pathol.* 1999, 23:82-87. [10.1097/0000478-199901000-00009](https://doi.org/10.1097/0000478-199901000-00009)

19. Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Ströbel P, Wardelmann E, Reichardt P: Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. *Br J Surg.* 2010, 97:1854-1859. [10.1002/bjs.7222](https://doi.org/10.1002/bjs.7222)
20. Blackstein ME, Blay JY, Corless C, et al.: Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. *Can J Gastroenterol.* 2006, 20:7. [10.1155/2006/434761](https://doi.org/10.1155/2006/434761)